Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -14.33, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 33.05M shares, increasing 13.43% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.36K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.40.